Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T15:40:54.051Z.
Calculation as of: 2026-10-06T15:40:54.051Z.
Quote observation: 2026-10-06T15:39:57.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 83c64da899843448fde498cf5e629ee28b7cf55c7878198a0aebccb75d14602d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2022-05-16.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
EV/FCF RATIO AVG TTM
N/A
EV/FCF RATIO AVG 3Y
N/A
EV/FCF RATIO AVG 5Y
N/A
EV/FCF RATIO AVG 10Y
N/A
EV/FCF RATIO AVG 15Y
N/A
EV/FCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Aspire Biopharma Holdings, Inc.
Market Cap
$1.04M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.11M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$873508.00
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | $1.04M | N/A | N/A | N/A | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.07M | N/A | N/A | N/A | N/A |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.11M | N/A | N/A | N/A | N/A |
| IM Cannabis Corp. (IMCC)vs › | $1.16M | N/A | 8.03x | 7.79x | 7.79x |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.17M | N/A | N/A | N/A | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $873967.00 | N/A | N/A | N/A | N/A |
| Decoy Therapeutics Inc. (DCOY)vs › | $856468.00 | N/A | N/A | N/A | N/A |
| Bone Biologics Corporation (BBLG)vs › | $873508.00 | N/A | N/A | N/A | N/A |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $832324.00 | N/A | N/A | N/A | N/A |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.21M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/FCF RATIO |
|---|---|
| 2022-05-16 | 60611.68x |
| 2022-05-13 | 60550.83x |
| 2022-05-12 | 60654.28x |
| 2022-05-11 | 60611.68x |
| 2022-05-10 | 60672.53x |
| 2022-05-09 | 60733.39x |
| 2022-05-06 | 60733.39x |
| 2022-05-05 | 61037.65x |
| 2022-05-04 | 60733.39x |
| 2022-05-03 | 60733.39x |
| 2022-05-02 | 60946.37x |
| 2022-04-29 | 60733.39x |
| 2022-04-28 | 60763.81x |
| 2022-04-27 | 60739.47x |
| 2022-04-26 | 60733.39x |
| 2022-04-25 | 60855.09x |
| 2022-04-22 | 60976.80x |
| 2022-04-21 | 60867.26x |
| 2022-04-20 | 60909.86x |
| 2022-04-19 | 60964.63x |
| 2022-04-18 | 60976.80x |
| 2022-04-14 | 60855.09x |
| 2022-04-13 | 60855.09x |
| 2022-04-12 | 60794.24x |
| 2022-04-11 | 60794.24x |
